Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

Official Title

Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy

Brief Summary

      Study to focus on the defining and managing the neuropsychological abnormalities of myotonic
      dystrophy and to find out if the neuropsychological abnormalities have any correlation with
      changes seen on Magnetic Resonance Imaging.

Detailed Description

      Given the prevalence of DM, and assistance from The Myotonic Dystrophy Foundation (letter),
      we anticipate full recruitment of 8-17 year old subjects with DM1. The genetic counselor will
      help recruit 20 DM1 subjects, and 20 comparably aged controls, all of whom will complete MRI
      and neuropsychological tests. We anticipate full participation in evoked potential and blood
      tests, but estimate 30% will permit a lumbar puncture for CSF evaluation - done at the LPCH
      Ambulatory Procedure Unit with sedation as necessary. In total 40 MRIs will be done over 2
      years, or 20 annually. Testing of Subjects

      All neuropsychological evaluations will be performed in the morning in attempt to standardize
      wakefulness and stamina. Dr. Day's assessment of clinical status (~45 min) utilizes the
      Stanford myotonic dystrophy questionnaire, the University of Rochester MDHI, and the muscular
      impairment rating scale (MIRS)57, and records vital signs, current medications, spirometer,
      and disease history and progression. Given the frequency of sleep disorders in DM, subjects
      will complete the Affiliated Sleep Questionnaire, an online collection of extensive
      information in standardized format (see letter Dr. Mignot). After the clinical and
      neuropsychological assessments the subject and family members will have lunch prior to the
      MRI(75 min). In the mid-afternoon subjects will have evoked potentials in the
      Electrodiagnostics Lab(~90 min) followed by a lumbar puncture (if consenting) and blood draw
      in the LPCH APU(90 min). Subjects return home the same day, and Ms. Paulose contacts them
      several days later for feedback.

Study Type


Primary Outcome

Define the neuropsychological abnormalities in Myotonic Dystrophy type 1


Myotonic Dystrophy Type 1


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

December 2013

Completion Date

December 2016

Primary Completion Date

December 2016

Eligibility Criteria

        Inclusion Criteria:

          -  20 subjects with Myotonic Dystrophy type 1 aged 8 to 17 years and 20 controls who are
             healthy volunteers or siblings of affected subjects.

        Exclusion Criteria:





8 Years - 17 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


John W Day, MD, PhD, 650-725-4341, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Stanford University

Study Sponsor

John W Day, MD, PhD, Principal Investigator, Stanford University

Verification Date

October 2014